J147

J147 is an experimental drug with reported effects against both Alzheimer's disease and ageing in mouse models of accelerated aging. The drug was developed at the Salk Institute for Biological Studies by a team led by David Schubert.

History

J147 was first synthesized in 2011. The development of J147 was based on the examination of cellular pathways in old human brain cells. Instead of focusing on the pathologies of Alzheimer's disease, the team at Salk Institute decided to screen for molecules that targeted the major pathways of aging.

Mechanism of Action

J147 works by binding to a protein found in mitochondria, the energy-generating powerhouses of cells, leading to an array of beneficial effects. It enhances the function of mitochondria, providing neurons with protection against age-associated declines in energy production.

Research and Development

In mouse models of accelerated aging, J147 improved memory and prevented the loss of neuronal cells. It also extended the lifespan of healthy mice. In 2018, the team at Salk Institute discovered that the drug binds to a protein called ATP synthase, specifically inhibiting its activity in a subunit called c-Fo.

Clinical Trials

As of 2021, J147 is in Phase 1 clinical trials for Alzheimer's disease. The trials are being conducted by a company called Abrexa Pharmaceuticals.

See Also

• Alzheimer's disease
• ATP synthase
• Mitochondria
• Salk Institute for Biological Studies

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia